Achieving an Undetectable PSA After Radiotherapy for Biochemical Progression After Radical Prostatectomy Is an Independent Predictor of Biochemical Outcome—Results of a Retrospective Study

Continuous prostate-specific antigen rise despite salvage radiotherapy following radical prostatectomy: Pattern of clinical relapse and predictive factors

“…Of course, there is also a certain risk of disease progression in patients with initial PSA response (7-10). However, previous studies suggest that the time interval between post-radiotherapy BCR and overt metastatic disease is often so long that life expectancy is not affected (11,12). Our patients with continuous PSA increase had a median age of 64 years and a median interval to radiological recurrence of 43 months.…”

Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

“…Approximately 60% of patients who are treated with SRT before the PSA level rises to >0.5 ng/mL will achieve an undetectable PSA level, providing long-term PSA control in nearly half of them. 8 However, after SRT, some patients may still experience further clinical progression, including DM and cancer-related death. The effect of SRT on the long-term outcomes including metastasis-free survival (MFS) and overall survival-especially in Chinese patients-is not well understood.…”

The German S3 Guideline Prostate Cancer

“…Meanwhile, the results of three randomized trials (SWOG [31], EORTC [4] and ARO [34,35]) with focus on adjuvant radiotherapy in the pT3 situation are available. Radiation treatment with 60-64 Gy improves local relapse-free survival at 5 years by about 20%, whereas the Kaplan-Meier estimates diverge already 2-3 years after treatment for metastases-free survival and 5-6 years after treatment for overall survival [31].…”

“…Radiation treatment with 60-64 Gy improves local relapse-free survival at 5 years by about 20%, whereas the Kaplan-Meier estimates diverge already 2-3 years after treatment for metastases-free survival and 5-6 years after treatment for overall survival [31]. A 20% advantage after 5 years was also seen in patients reaching a PSA < 0.1 ng/ml after radical prostatectomy [34,35]. The SWOG study [31] showed a significant prolongation of overall survival after adjuvant radiotherapy of about 2 years after a median follow-up of almost 13 years.…”

“…The SWOG study [31] showed a significant prolongation of overall survival after adjuvant radiotherapy of about 2 years after a median follow-up of almost 13 years. The highest benefit after adjuvant radiation treatment was seen in patients with a pT3 tumor and positive margins (30% higher biochemical no-evidence-of-disease [NED] rates after 5 years) [32,34,35]. Therefore, the patient shall be informed about adjuvant radiotherapy in a pT3 R1 situation.…”